Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (DE:3G0)
FRANKFURT:3G0
Altimmune (3G0) Stock Price & Analysis
5 Followers
3G0 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.97 - €13.70
Previous Close€6.66
Volume1.50K
Average Volume (3M)717.00
Market Cap
€467.78M
Enterprise Value€290.13M
Total Cash (Recent Filing)$197.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta0.51
Next Earnings
May 09, 2024EPS Estimate
-€0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding70,895,286
10 Day Avg. Volume488
30 Day Avg. Volume717
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.58
Price to Sales (P/S)11634.49
Price to Cash Flow (P/CF)-7.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue681.05
Enterprise Value/Gross Profit681.05
Enterprise Value/Ebitda-3.28
Forecast
1Y Price Target
€21.79Price Target Upside227.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Altimmune News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyPemvidutide demonstrates strong potential in treating obesity and NASH by uniquely combining anti-fibrotic effects, liver de-fatting properties, and favorable weight loss distribution.
Financial StabilityAltimmune's robust financial health, evidenced by a significant cash reserve, underpins the company's ability to sustain its operations and fund future developments.
Strategic PartnershipsOngoing discussions about strategic partnerships for Phase 3 development and commercialization signal growing confidence in Pemvidutide's market potential.
Bears Say
Clinical TrialsHigh incidence of gastrointestinal adverse events, such as nausea, in Phase 2 trials could be a concern for pemvidutide's user acceptance.
Market CompetitionThe emergence of other effective weight loss therapies could pose additional risk to ALT's ability to find a strategic partner for pemvidutide.
Pipeline DevelopmentThe discontinuation of HepTcell, a T cell immunotherapy for hepatitis B, due to insufficient response in Phase 2 trials may impact the company's research pipeline.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.94% Other Institutional Investors
99.06% Public Companies and
Individual Investors
3G0 FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was €1.97 and its highest was €13.70 in the past 12 months.
What is Altimmune Inc’s market cap?
Currently, no data Available
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is May 09, 2024 which is in 4 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Mar 27, 2024. The company reported -€0.504 earnings per share for the quarter, missing the consensus estimate of -€0.425 by -€0.079.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc does not currently pay dividends.
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -€0.35.
How many shares outstanding does Altimmune Inc have?
Currently, no data Available
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -€0.504 in its last earnings report, missing expectations of -€0.425. Following the earnings report the stock price went up 4.177%.
Which hedge fund is a major shareholder of Altimmune Inc?
Among the largest hedge funds holding Altimmune Inc’s share is Ardsley Advisory Partners. It holds Altimmune Inc’s shares valued at 4M.
---
Altimmune Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€21.79 (227.03% Upside)
€21.79 (227.03% Upside)
Blogger Sentiment
Bullish
DE:3G0 Sentiment 98%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.68%
12-Months-Change
Fundamentals
Return on Equity
-46.63%
Trailing 12-Months
Asset Growth
1.79%
Trailing 12-Months
Company Description
Altimmune Inc
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
---
3G0 Earnings Call
Q4 2024
0:00 / 0:00
---
3G0 Stock 12 Months Forecast
Average Price Target
€21.79
▲(227.03% Upside)
Technical Analysis
Best Analysts Covering 3G0
1 Year
1 Year Success Rate
14/33 ratings generated profit
1 Year Average Return
+5.91%
reiterated a buy rating last month
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 42.42% of your transactions generating a profit, with an average return of +5.91% per trade.
---